Drug Trial Radar · NCT06465368
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
Jul 11, 2024
Primary completion
Jul 10, 2025
Study completion Jul 10, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the effects of the study medicine PF-07220060 plus letrozole, compared with the effects of taking letrozole alone without PF-07220060 for treatment of breast cancer. This study is seeking for participants who are: * women of age 18 years and older post menopause (either naturally or surgically). * confirmed to have Hormone receptor (HR) positive, Human epidermal growth factor receptor 2 (HER2) negative breast cancer. HER2 negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. * not been treated for their cancer before this study. Participants will be randomly assigned (like flipping a coin) to receive the treatment (PF-07220060 plus letrozole) or letrozole alone. Both PF-07220060 and letrozole are taken by mouth. PF-07220060 will be taken twice a day for 14 days. Letrozole will be taken once a day for 14 days. Participants will have a screening period for up to 28 days. If deemed fit, they will receive study treatment for 14 days, and then will have a follow-up visit about 28 days after their last dose. All participants will have at least one biopsy during the study. Biopsy is the removal of cells or tissues for examining. All participants will have a biopsy on Day 14. Additional assessments for safety including blood draws and interviews done by the site staff will be completed during the study.
Conditions
- Breast Cancer
Interventions
PF-07220060Drug
PF-07220060 given as tablet by mouth twice a day for 14 days.
letrozoleDrug
Letrozole given as tablet by mouth once a day for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14Time frame: Day 14
Locations
51 sites in 13 countries. Site status is shown where the registry gives one.
Advocate Good Shepherd Hospital
Barrington, Illinois
AMG -Crystal Lake
Crystal Lake, Illinois
Advocate Lutheran General Hospital
Park Ridge, Illinois
Advocate Medical Group
Park Ridge, Illinois
Baylor College of Medicine Medical Center
Houston, Texas
Baylor St. Luke's Medical Center
Houston, Texas
Ben Taub General Hospital
Houston, Texas
Harris Health System - Smith Clinic
Houston, Texas
O'Quinn Medical Tower - McNair Campus
Houston, Texas
START San Antonio
San Antonio, Texas
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Institut Jules Bordet
Anderlecht, Bruxelles-capitale, Région de, Belgium
UZ Leuven
Leuven, Vlaams-brabant, Belgium
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer
Rennes, Ille-et-vilaine, France
Centre de Cancérologie du Grand Montpellier
Montpellier, Languedoc-roussillon, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, Loire-atlantique, France
CHU de Saint-Etienne
Saint Priest En Jarez, Pays de la Loire Region, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, Rhône, France
HCL, Centre Hospitalier Lyon Sud
Saint-Genis-Laval, Rhône, France
Gustave Roussy
Villejuif, Val-de-marne, France
CaritasKlinikum Saarbrücken St. Theresia
Saarbrücken, Saarland, Germany
Ospedale Antonio Perrino
Brindisi, Italy
Azienda Ospedaliero Universitaria Maggiore della Carità
Novara, Italy
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
Meldola, Emilia-Romagna, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, Italy
Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno
Livorno, Tuscany, Italy
AIDPORT Sp. z o.o.
Skórzewo, Greater Poland Voivodeship, Poland
Pratia MCM Krakow
Krakow, Lesser Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu
Przemyśl, Podkarpackie Voivodeship, Poland
Narodny onkologicky ustav
Bratislava, Slovakia
Nemocnica AGEL Komarno
Komárno, Nitra Region, Slovakia
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], South Korea
Hospital Universitario San Cecilio
Granada, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital General Universitario de Elche
Elche, Alicante, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], Spain
Hospital Jerez de la Frontera
Jerez de la Frontera, Cádiz, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalunya [cataluña], Spain
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.